Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

Misako Nagasaka; Cliff Molife; Zhanglin Lin Cui; Victoria Stefaniak; Xiaohong Li; Sangmi Kim; Hsui Yung Lee; Julia Beyrer; George Blumenschein

doi:10.2217/fon-2022-0099

Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

Misako Nagasaka, Cliff Molife, Zhanglin Lin Cui, Victoria Stefaniak, Xiaohong Li, Sangmi Kim, Hsui Yung Lee, Julia Beyrer, George Blumenschein

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.

Original language	English (US)
Pages (from-to)	1963-1977
Number of pages	15
Journal	Future Oncology
Volume	18
Issue number	16
DOIs	https://doi.org/10.2217/fon-2022-0099
State	Published - May 2022

Keywords

Adjustment
Anti-PD-1
Entropy balancing
Immunotherapy
Inverse probability reweighting
Nonsquamous non-small-cell lung cancer
ORIENT-11
Progression-free survival
Sintilimab

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2022-0099

Cite this

@article{d5e2ed9968964519bf7f3f4820c60da1,

title = "Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer",

abstract = "Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.",

keywords = "Adjustment, Anti-PD-1, Entropy balancing, Immunotherapy, Inverse probability reweighting, Nonsquamous non-small-cell lung cancer, ORIENT-11, Progression-free survival, Sintilimab",

author = "Misako Nagasaka and Cliff Molife and Cui, {Zhanglin Lin} and Victoria Stefaniak and Xiaohong Li and Sangmi Kim and Lee, {Hsui Yung} and Julia Beyrer and George Blumenschein",

note = "Publisher Copyright: {\textcopyright} 2022 Eli Lilly and Company.",

year = "2022",

month = may,

doi = "10.2217/fon-2022-0099",

language = "English (US)",

volume = "18",

pages = "1963--1977",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "16",

}

TY - JOUR

T1 - Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

AU - Nagasaka, Misako

AU - Molife, Cliff

AU - Cui, Zhanglin Lin

AU - Stefaniak, Victoria

AU - Li, Xiaohong

AU - Kim, Sangmi

AU - Lee, Hsui Yung

AU - Beyrer, Julia

AU - Blumenschein, George

PY - 2022/5

Y1 - 2022/5

N2 - Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.

AB - Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.

KW - Adjustment

KW - Anti-PD-1

KW - Entropy balancing

KW - Immunotherapy

KW - Inverse probability reweighting

KW - Nonsquamous non-small-cell lung cancer

KW - ORIENT-11

KW - Progression-free survival

KW - Sintilimab

UR - http://www.scopus.com/inward/record.url?scp=85129191706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129191706&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0099

DO - 10.2217/fon-2022-0099

M3 - Article

C2 - 35354280

AN - SCOPUS:85129191706

SN - 1479-6694

VL - 18

SP - 1963

EP - 1977

JO - Future Oncology

JF - Future Oncology

IS - 16

ER -

Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this